

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

KP-4

RRID:CVCL_1338

Type: Cell Line

Proper Citation

RRID:CVCL_1338

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1338

Proper Citation: RRID:CVCL_1338

Description: Cell line KP-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic carcinoma

Defining Citation: [PMID:20164919](#), [PMID:20215515](#), [PMID:21559554](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KP-4

Synonyms: KP 4, KP4

Cross References: CLO:CLO_0037110, CLO:CLO_0050109, EFO:EFO_0006623, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:613, BioSample:SAMN03472375, BioSample:SAMN03472831, BioSample:SAMN10987858, cancercellines:CVCL_1338, Cell_Model_Passport:SIDM00301, CGH-DB:9373-4, ChEMBL-Cells:ChEMBL3308751, ChEMBL-Targets:ChEMBL1075482, Cosmic:753572, Cosmic-CLP:753572, DepMap:ACH-000265, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:753572, GEO:GSM827214, GEO:GSM887237, GEO:GSM888311, GEO:GSM1374602, GEO:GSM1670004, JCRB:JCRB0182, LiGeA:CCLE_454, LINCS_LDP:LCL-1725, PharmacDB:KP4_785_2019, PRIDE:PXD030304, Progenetix:CVCL_1338, PubChem_Cell_line:CVCL_1338, RCB:RCB1005, Wikidata:Q54900371

ID: CVCL_1338

Record Creation Time: 20220427T220707+0000

Record Last Update: 20260829T234426+0000

Ratings and Alerts

No rating or validation information has been found for KP-4.

No alerts have been found for KP-4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lin Q, et al. (2026) Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(11), 2279.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Ruiz CF, et al. (2026) Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. Cancer discovery.

Lefrançois G, et al. (2026) The role of ATP synthase subunit e (ATP5I) in mediating the metabolic and antiproliferative effects of metformin in cancer cells. eLife, 13.

Jain A, et al. (2025) Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. Science (New York, N.Y.), 387(6741), eadq8331.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell reports, 44(4), 115541.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Ishihara S, et al. (2025) Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. *iScience*, 28(3), 112057.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. *Cancer discovery*, 15(8), 1717.

Wu C, et al. (2025) Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts. *Cancer research communications*, 5(1), 195.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. *Nature communications*, 16(1), 4866.

Kumai J, et al. (2025) Metastatic breast cancer cells adapt to a soft environment with limited involvement of mechanotransduction. *Experimental cell research*, 450(2), 114629.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. *Cancer research*, 85(18), 3540.

Campos AD, et al. (2025) A STAT3/integrin axis accelerates pancreatic cancer initiation and progression. *Cell reports*, 44(8), 116010.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. *Science advances*, 11(42), eadx0632.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Ishihara S, et al. (2025) Protocol to culture cells on genipin-mixed collagen gels with different stiffnesses. *STAR protocols*, 6(4), 104125.

Bhat KP, et al. (2024) CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis. *Cell reports*, 43(6), 114345.

Lopes-Paciencia S, et al. (2024) A senescence restriction point acting on chromatin integrates oncogenic signals. *Cell reports*, 43(4), 114044.

Kato H, et al. (2024) The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. *Cancer medicine*, 13(16), e70124.